QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pacbio-announced-innovations-to-its-revio-and-vega-platforms-to-lower-sequencing-costs-add-new-multiomic-capabilities-and-expand-support-for-regulated-research-environments

The advancements center on new SPRQ-Nx sequencing chemistry and consumables, which are designed to deliver PacBio's most af...

 pacbios-hifi-technology-selected-as-primary-platform-for-korean-pangenome-reference-project

MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-...

 pacbios-revio-systems-chosen-by-national-institute-on-aging-long-life-family-study-to-sequence-genomes-of-7800-participants-in-longevity-study

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that ...

 pacbio-enters-high-throughput-carrier-screening-market-with-expanded-puretarget-kits-for-inherited-conditions

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into...

 epicypher-joins-pacbio-compatible-program-to-enhance-single-molecule-chromatin-sequencing-with-cutana-hia5-enzyme

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher...

 piper-sandler-maintains-neutral-on-pacific-biosciences-raises-price-target-to-15

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price targe...

 pacific-biosciences-q2-adj-eps-013-beats-017-estimate-sales-39766m-beat-36886m-estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $...

 pacbio-and-partners-publish-benchmark-study-in-nature-methods-enhancing-genomic-accuracy-and-reducing-ai-variant-errors-by-34

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of ...

Core News & Articles

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of diseaseBOSTON, Jul...

Core News & Articles

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of diseaseBOSTON, Jul...

Core News & Articles

Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read s...

 barclays-maintains-equal-weight-on-pacific-biosciences-lowers-price-target-to-15

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target fr...

 target-als-partners-with-pacbio-to-launch-largest-global-whole-genome-sequencing-initiative-for-als-to-date

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely av...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION